Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

ORA reorganizes, and HHS’ Office of Inspector General plans investigations of FDA programs. More regulatory news.

You may also be interested in...



HHS OIG Targets Medicare DME Costs In 2013 Work Plan

The Office of Inspector General’s fiscal 2013 work plan outlines new projects to monitor costly overpayments for Medicare durable medical equipment and realize additional cost savings in the Medicaid program.

Regulatory News In Brief

CDRH issues simplified SOPs for resolving differences of scientific, regulatory or clinical opinion among staffers. More regulatory news.

Judge Orders FDA To Hand Over Whistleblower Surveillance Documents

In the latest turn of events for FDA, a federal judge has ordered the agency to hand over thousands of documents accumulated from monitoring employees’ communications.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel